GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
These findings indicate that certain GLP1RAs may reduce the need for future renal replacement therapy, lower treatment costs, and improve quality of life for patients with diabetic kidney disease
If B12 levels are low, treatment is usually simple
While semaglutide is Category C and animal studies haven't shown major birth defects, human pregnancy data is limited
For optimal results, incorporate this product into your morning and evening skincare regimen